Antisense Oligonucleotide Silencing Reverses Abnormal Neurochemistry in Spinocerebellar Ataxia 3 Mice.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
10
05
2023
received:
13
12
2022
accepted:
17
05
2023
pmc-release:
01
10
2024
medline:
2
10
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
ppublish
Résumé
Spinocerebellar ataxia type 3 (SCA3) is the most common dominantly inherited ataxia, and biomarkers are needed to noninvasively monitor disease progression and treatment response. Anti-ATXN3 antisense oligonucleotide (ASO) treatment has been shown to mitigate neuropathology and rescue motor phenotypes in SCA3 mice. Here, we investigated whether repeated ASO administration reverses brainstem and cerebellar neurochemical abnormalities by magnetic resonance spectroscopy (MRS). Symptomatic SCA3 mice received intracerebroventricular treatment of ASO or vehicle and were compared to wild-type vehicle-treated littermates. To quantify neurochemical changes in treated mice, longitudinal 9.4T MRS of cerebellum and brainstem was performed. Acquired magnetic resonance (MR) group means were analyzed by 2-way analysis of variance mixed-effects sex-adjusted analysis with post hoc Sidak correlation for multiple comparisons. Pearson correlations were used to relate SCA3 pathology and behavior. MR spectra yielded 15 to 16 neurochemical concentrations in the cerebellum and brainstem. ASO treatment in SCA3 mice resulted in significant total choline rescue and partial reversals of taurine, glutamine, and total N-acetylaspartate across both regions. Some ASO-rescued neurochemicals correlated with reduction in diseased protein and nuclear ATXN3 accumulation. ASO-corrected motor activity correlated with total choline and total N-acetylaspartate levels early in disease. SCA3 mouse cerebellar and brainstem neurochemical trends parallel those in patients with SCA3. Decreased total choline may reflect oligodendrocyte abnormalities, decreased total N-acetylaspartate highlights neuronal health disturbances, and high glutamine may indicate gliosis. ASO treatment fully or partially reversed select neurochemical abnormalities in SCA3 mice, indicating the potential for these measures to serve as noninvasive treatment biomarkers in future SCA3 gene silencing trials. ANN NEUROL 2023;94:658-671.
Identifiants
pubmed: 37243335
doi: 10.1002/ana.26713
pmc: PMC10543567
mid: NIHMS1904835
doi:
Substances chimiques
Oligonucleotides, Antisense
0
Glutamine
0RH81L854J
Biomarkers
0
Choline
N91BDP6H0X
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
658-671Subventions
Organisme : NIBIB NIH HHS
ID : P41 EB027061
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS111154
Pays : United States
Organisme : NINDS NIH HHS
ID : P30 NS076408
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS122751
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS106670
Pays : United States
Informations de copyright
© 2023 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Mov Disord Clin Pract. 2019 Jul 10;6(7):549-558
pubmed: 31538089
Ann Clin Transl Neurol. 2021 Jul;8(7):1543-1556
pubmed: 34019331
Mov Disord. 2020 Sep;35(9):1679-1684
pubmed: 32515873
Magn Reson Med. 1986 Dec;3(6):823-33
pubmed: 3821461
Magn Reson Med. 1999 Apr;41(4):649-56
pubmed: 10332839
Neurobiol Dis. 2010 Oct;40(1):163-76
pubmed: 20510362
Cerebellum. 2011 Jun;10(2):208-17
pubmed: 20838948
Ann Neurol. 2018 Apr;83(4):816-829
pubmed: 29575033
J Vis Exp. 2013 May 12;(75):e50326
pubmed: 23712122
Mov Disord. 2021 Oct;36(10):2273-2281
pubmed: 33951232
Lancet Neurol. 2015 Nov;14(11):1101-8
pubmed: 26377379
Acta Neuropathol Commun. 2022 Mar 19;10(1):37
pubmed: 35305685
NMR Biomed. 2000 May;13(3):129-53
pubmed: 10861994
Cerebellum. 2021 Feb;20(1):41-53
pubmed: 32789747
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385727
J Biol Chem. 1999 Jan 15;274(3):1715-22
pubmed: 9880552
Hum Mol Genet. 2002 May 1;11(9):1075-94
pubmed: 11978767
Mov Disord. 2020 Oct;35(10):1774-1786
pubmed: 32621646
Front Neurosci. 2023 Feb 15;17:1118429
pubmed: 36875652
Front Neurol. 2020 Aug 26;11:902
pubmed: 32982927
Mol Ther Nucleic Acids. 2017 Jun 16;7:200-210
pubmed: 28624196
Magn Reson Med. 2000 Feb;43(2):319-23
pubmed: 10680699
Nucleosides Nucleotides Nucleic Acids. 2003 Apr;22(4):461-8
pubmed: 12885126
Mov Disord. 2010 Jul 15;25(9):1253-61
pubmed: 20310029
J Neurol Sci. 2021 May 15;424:117417
pubmed: 33836316
Cells. 2022 Aug 22;11(16):
pubmed: 36010688
Neurobiol Dis. 2015 Jan;73:174-88
pubmed: 25301414
J Neuroimaging. 2009 Jan;19(1):9-12
pubmed: 18482370
Neurosci Biobehav Rev. 2020 Jan;108:854-865
pubmed: 31838195
Mov Disord. 1992;7(3):193-203
pubmed: 1620135
PLoS One. 2013 Jul 23;8(7):e69782
pubmed: 23936100
J Neurosci. 2022 Feb 23;42(8):1604-1617
pubmed: 35042771
Magn Reson Med. 2012 Apr;67(4):891-7
pubmed: 21748799
Prog Neurobiol. 2013 May;104:38-66
pubmed: 23438480
Ann Neurol. 1998 Feb;43(2):244-52
pubmed: 9485066
J Magn Reson. 2001 Dec;153(2):155-77
pubmed: 11740891
Hepatology. 1996 Oct;24(4):919-23
pubmed: 8855198
Magn Reson Med. 1993 Dec;30(6):672-9
pubmed: 8139448
Cerebellum. 2023 Jan 4;:
pubmed: 36598718
Ann Neurol. 2018 Jul;84(1):64-77
pubmed: 29908063
Mov Disord. 2015 Apr 15;30(5):662-70
pubmed: 25773989
Stem Cell Res. 2019 Aug;39:101504
pubmed: 31374463
JAMA Neurol. 2019 Jun 1;76(6):650-656
pubmed: 30933216
Neurobiol Dis. 2020 Feb;134:104635
pubmed: 31669734
Mol Ther. 2013 Oct;21(10):1898-908
pubmed: 23765441
Lancet Neurol. 2010 Sep;9(9):885-94
pubmed: 20723845
Neurobiol Dis. 2015 Feb;74:158-66
pubmed: 25446943
J Neurosci. 2010 Mar 10;30(10):3831-8
pubmed: 20220018
Cerebellum. 2020 Aug;19(4):536-543
pubmed: 32367276